Clinical Trials

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

Research, Medical Supplies, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Private Securities Litigation Reform Act, Degenerative disease, N501Y, Government, Safety, NIH, Annual report, Company, Severe acute respiratory syndrome coronavirus 2, SEC, Therapy, Vaccine, COVID-19, National, U.S. Securities and Exchange Commission, Omicron, View, Risk, Biotechnology, MRNA, RNA, Science, RNA transfection, Infection, Intention, Fertilizer
Friday, November 26, 2021 - 8:31pm

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.
  • This strategy includes three levels of response should the currently authorized 50 g booster dose of mRNA-1273 prove insufficient to boost waning immunity against the Omicron variant.
  • The first candidate (mRNA-1273.211) includes several mutations present in the Omicron variant that were also present in the Beta variant of concern1.
  • The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant, said Stphane Bancel, Chief Executive Officer of Moderna.

Global Anatomic Pathology Market Forecasts to 2026: Increasing Number of Clinical Trials Pertaining to Cancer Drugs - ResearchAndMarkets.com

Pharmaceutical, Health, Oncology, Clinical Trials, Product, Product-service system, Hospital, Population, CAGR, Region, Awareness, Diagnosis, Cancer, Prevalence, USD, Physician, Incidence, Conditional sentence, Disease, Pathology, Growth, Medical imaging
Friday, November 26, 2021 - 1:02pm

The "Anatomic Pathology Market by Product & Service, Application, End-user, and Region - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anatomic Pathology Market by Product & Service, Application, End-user, and Region - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7%.
  • The anatomic pathology services segment accounted for the highest growth rate in the anatomic pathology market, by product and service, during the forecast period
    Based on product & service, the anatomic pathology market is segmented into services, consumables, and instruments.
  • Based on end-user, the anatomic pathology market is segmented into hospital laboratories, clinical laboratories, and other end users.

Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea

Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Genetics, Clinical Trials, Transfer, Policy, Patient, Plasmid, Developing country, Technology, Partnership, CHL, Cancer, Clinical trial, Inflammation, Human, KOSDAQ, Cadila Healthcare, Therapy, COVID-19, Vaccine, COVID 19, DNA, US, Organic acid, US FDA, Degenerative disease, EUA, Edwards Lifesciences, Technology transfer, COVID, Pharmaceutical industry
Friday, November 26, 2021 - 1:00pm

Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) and Cadila Healthcare Ltd, a part of the Zydus Group, today announced that they have entered a Manufacturing License and Technology Transfer Agreement for the worlds first plasmid DNA vaccine (ZyCoV-D).
  • Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem.
  • Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80 million or more doses of the plasmid DNA vaccine in 2022.
  • Mr. Ki Young Sohn, Chairman of Enzychem Lifesciences said: Today marks an important milestone for our vaccine consortium as we embark on the manufacturing of the worlds first- in-class DNA vaccine for humans.

Canon Medical Signals Its Support for a Multicenter Ultrasound Liver Evaluation and Assessment Study

Surgery, Other Health, Software, Other Science, Radiology, Research, Oncology, Hardware, Mental Health, Medical Devices, Infectious Diseases, Hospitals, Technology, Genetics, Clinical Trials, Cardiology, Science, Biotechnology, Practice Management, Alternative Medicine, Physical Therapy, Nursing, Managed Care, Medical Supplies, Health, FDA, Patient, Heart, Liver disease, International University, Safety, Multicenter trial, RSNA, General manager, Diabetes, Health care, Iliad, Population, Health, Canon Medical Systems Corporation, Solution, Dispersion, Fatty liver disease, Professor, Trust, Center, Risk, Research, Life, Knowledge, NASH, CT, International University of Health and Welfare, Inflammation, Cardiovascular disease, Quality of life, Medical imaging
Friday, November 26, 2021 - 1:00pm

Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming to evaluate quantitative ultrasound imaging tools against liver biopsy (the current clinical gold standard), available on the Aplio Liver Package for the assessment of Steatosis, Fibrosis, and Inflammation in the clinical environment.

Key Points: 
  • Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming to evaluate quantitative ultrasound imaging tools against liver biopsy (the current clinical gold standard), available on the Aplio Liver Package for the assessment of Steatosis, Fibrosis, and Inflammation in the clinical environment.
  • This Multicenter study is focusing on the assessment of NASH (Non-Alcoholic SteatoHepatitis) using non-invasive innovative ultrasound liver imaging techniques against the current gold standard of liver biopsy.
  • The global burden of liver disease, along with its significant individual, community and financial implications, has driven ultrasound development of non-invasive, safe tools.
  • At Canon Medical, we work hand in hand with our partners - our medical, academic and research community.

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials
Friday, November 26, 2021 - 11:45am

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19.
  • Merck has shared these additional analyses with the FDA and they will be presented to the FDAs Antimicrobial Drugs Advisory Committee on Nov. 30th.
  • Since licensed by Ridgeback, all funds used for the development of molnupiravir have been provided by Merck and Ridgeback.
  • The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update

Biotechnology, Pharmaceutical, Health, Clinical Trials, CANF, Patient, Research, Institute of Liver and Biliary Sciences, Liver disease, Insurance, Safety, Psoriasis, Alimentary Pharmacology & Therapeutics, Cytokine release syndrome, Company, American Association for the Study of Liver Diseases, Use, NYSE, Exercise, Rheumatoid arthritis, Cancer, Diagnosis, Liver, AASLD, COVID-19, Corporation, Liver cancer, Public relations, Treatment, Investment, Non-alcoholic fatty liver disease, Hepatocellular carcinoma, Patent, Steatohepatitis, NASH, HCC, Therapy, American Association, Association, National Core Indicators, Gastroenterology, TASE, IP, Pharmaceutical industry, Medical device, Cryptocurrency
Friday, November 26, 2021 - 12:00pm

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021.
  • Corporate and Clinical Development Highlights Include:
    Completed Patient Enrollment in Phase III Psoriasis Study The Phase III Comfort study completed patient enrollment.
  • Financial income, net for the nine months ended September 30, 2021 was $0.31 million compared to financial expense, net of $0.22 million for the same period in 2020.
  • The Company's consolidated financial results for the nine months ended September 30, 2021 are presented in accordance with US GAAP Reporting Standards.

Meniere's Disease Pipeline Research Report 2021: Comprehensive Insights About 10+ Companies and 10+ Pipeline Drugs - ResearchAndMarkets.com

Health, Clinical Trials, Patient, Lung, News, Discovery, Retina, Fibrosis, Tinnitus, Technology, Brain, Acquisition, GPX, Disease, Kidney, Clinical trial, Mergers and acquisitions, Therapy, Ototoxicity, NDA, Fast Track, Sensorineural hearing loss, III, FDA, Cystic fibrosis, Neuropsychiatric Disease and Treatment, Glutathione peroxidase, Lists of diseases, II, Dietary supplement, Pharmaceutical industry
Thursday, November 25, 2021 - 3:34pm

This "Meniere's Disease - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere's Disease pipeline landscape.

Key Points: 
  • This "Meniere's Disease - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Meniere's Disease pipeline landscape.
  • A detailed picture of the Meniere's Disease pipeline landscape is provided which includes the disease overview and Meniere's Disease treatment guidelines.
  • The assessment part of the report embraces, in depth Meniere's Disease commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Meniere's Disease R&D.

Encyclopedia of Behavioral Neuroscience: Cognitive Psychology, Cognitive Science, Clinical Neurology, Neuroanatomy, and Neurophysiology, Edition No. 2 (2021) - ResearchAndMarkets.com

Biotechnology, Health, Clinical Trials, Method, Neuroimaging, Perception, Behavior, Neuroscience, Brain, Encyclopedia, Memory, Cognitive science, Psychiatry, Student, Human, Foundation, Cognition, Animal, Lists of diseases, Behavioral neuroscience, Technology, Research, Genetics, Psychology, Education, Neurology, Science, Ethics, Diffusion, Diffusion MRI, Medical imaging, Toy
Thursday, November 25, 2021 - 3:15pm

2" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering

Key Points: 
  • 2" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering
    Behavioral Neuroscience is a relatively recent discipline which unifies different fields encompassing Cognitive Psychology, Cognitive Science, Clinical Neurology, Neuroanatomy, and Neurophysiology.
  • Published in 2010, it comprised 212 articles and was a unique and essential resource for students and professionals in several fields including neuroscience, psychology, neurology, psychiatry, and cognitive science.
  • It was by far the most comprehensive reference work available addressing the advances in all the field of behavioral neuroscience.
  • Clinical Neuroanatomy (including Diffusion Tensor Imaging), Brain structures and functions (including the senses, biorhythms, plasticity and the perceptual/motor systems)
    2.

Molecular Medical Microbiology Encyclopedia: Edition No. 3 (2021) - ResearchAndMarkets.com

Biotechnology, Health, Clinical Trials, Prevalence, Technology, Student, Infection, Edition, Pharmaceutical industry, Vaccine
Thursday, November 25, 2021 - 3:13pm

The "Molecular Medical Microbiology.

Key Points: 
  • The "Molecular Medical Microbiology.
  • Molecular Medical Microbiology, Third Edition presents the latest release in what is considered to be the first book to synthesize new developments in both molecular and clinical research.
  • The molecular age has brought about dramatic changes in medical microbiology, along with great leaps in our understanding of the mechanisms of infectious disease.
  • Written by experts in the field, chapters include cutting-edge information and clinical overviews for each major bacterial group, along with the latest updates on vaccine development, molecular technology and diagnostic technology.

Global Graves' Ophthalmopathy Clinical Trials Market Research Report, H2 2021 Review - ResearchAndMarkets.com

Optical, Health, Clinical Trials, E7, G7, Decision-making, Clinical trial, Graves' ophthalmopathy, E7 (countries), Trial, Ophthalmology, Grave, Pharmaceutical industry
Thursday, November 25, 2021 - 1:00pm

The "Graves' Ophthalmopathy - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Graves' Ophthalmopathy - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides top line data relating to the clinical trials on Graves' Ophthalmopathy.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).